Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome

Eur J Cancer. 2024 May:202:114027. doi: 10.1016/j.ejca.2024.114027. Epub 2024 Mar 16.

Authors

Stefano H Byer¹, Colten Stewart², Shareef Mansour², Udhayvir S Grewal³

Affiliations

¹ Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.
² Division of Cardiology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.
³ Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals, Iowa City, IA, United States. Electronic address: grewaludhayvir@gmail.com.

PMID: 38507971
DOI: 10.1016/j.ejca.2024.114027

No abstract available

Publication types

Letter

MeSH terms

Abatacept / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects
Muscle Weakness
Myocarditis* / chemically induced
Myocarditis* / drug therapy
Myositis* / chemically induced
Myositis* / drug therapy
Nitriles*
Pyrazoles*
Pyrimidines*
Salvage Therapy
Steroids / therapeutic use

Substances

Abatacept
Immune Checkpoint Inhibitors
ruxolitinib
Steroids
Nitriles
Pyrazoles
Pyrimidines